Targeted therapies such as Alemtuzumab, a monoclonal antibody against CD52, have shown promise in refractory disease with an overall response rate of 60%, but are limited by cost, accessibility, and immunosuppression-associated infections [5]. This evidence concerns the gene CD52 and infection.